BioNTech (BNTX) shares dropped 8% after discontinuing its Phase 2 mRNA colorectal cancer vaccine trial due to futility and survival imbalances. The post BioNTech (BNTX) Shares Plunge 8% Following Colorectal Cancer Vaccine Trial Discontinuation appeared first on Blockonomi.
BioNTech (BNTX) Shares Plunge 8% Following Colorectal Cancer Vaccine Trial Discontinuation
其他语言标题
- EnglishBioNTech (BNTX) shares plunged 8% following the discontinuation of its colorectal cancer vaccine trial.
- 한국어BioNTech (BNTX) 주가, 대장암 백신 임상시험 중단 소식에 8% 급락